Business Context and Reporting Period
This Form 10-Q covers the quarter ended March 31, 1996, for ACCESS Pharmaceuticals, Inc. (formerly Chemex Pharmaceuticals, Inc.). On January 25, 1996, the Company completed a reverse acquisition merger with ACCESS Pharmaceuticals, Inc. (API), a Texas corporation. While Chemex remains the legal entity, API is treated as the acquirer for accounting purposes. The Company's focus has shifted from skin disease treatments to developing endothelial binding technology for targeted delivery of oncology therapeutics and diagnostic imaging agents.
Key Financial Metrics
| Metric | Q1 1996 | Q1 1995 |
|---|---|---|
| Revenues | $165,000 | $135,000 |
| Total Expenses | $8,880,000 | $421,000 |
| Net Loss | $(8,685,000) | $(283,000) |
| Loss Per Share | $(0.34) | $(0.10) |
| Cash and Equivalents (End of Period) | $6,813,000 | $134,000 |
| Working Capital | $6,309,000 | $(515,000) |
| Research & Development Spend | $181,000 | $215,000 |
Liquidity: Working capital increased by $6.8 million, driven by a $6 million private placement of 8.57 million shares in March 1996 and the merger. Management believes current capital will fund operations through December 1997.
Material Changes vs. Prior Period
- Revenue Increase: Revenues rose $30,000 to $165,000, primarily due to $165,000 in option payments received for a third-party technology evaluation. This replaced the sponsored R&D revenue seen in 1995.
- Expense Surge: Total expenses jumped to $8.88 million from $421,000. This is largely due to a one-time non-cash write-off of $8,314,000 representing the excess purchase price over the fair value of Chemex's assets in the reverse acquisition.
- Operating Expenses: General and administrative expenses increased by $182,000 to $336,000 due to merger-related legal fees, private placement costs, and director fees. R&D expenses decreased slightly by $34,000.
- Cash Position: Cash balances grew from $30,000 at year-end 1995 to $6.81 million, reflecting the private placement proceeds and cash acquired in the merger.
Outlook, Risks, and Unusual Items
- Merger Accounting: The $8.3 million write-off is an unusual item resulting from the reverse acquisition accounting treatment. It significantly impacted the net loss but did not affect cash flow.
- Future Revenue: No royalty revenues are expected in 1996. The Company is awaiting FDA approval for Amlexanox (sold to Block Drug), but no sales have occurred to date.
- Development Pipeline: Two product candidates are anticipated to be ready for human testing in the first half of 1997. R&D spending is expected to increase as the Company hires scientific staff.
- Acquisition Activity: On April 26, 1996, the Company executed a letter of intent to acquire Tacora Corp. The purchase price is contingent on milestones and could involve stock valued up to $14 million.
- Risks: The Company is in a development stage with no assurance of successful product testing, future equity financing, or securing partners. It remains dependent on external capital to complete testing.
Investor Verification Checklist
- Verify the status of the Tacora Corp. acquisition and the specific milestones triggering the $14 million stock payment.
- Confirm the timeline for the registration statement for the 8.57 million shares issued in the March 1996 private placement (due within 90 days of issuance).
- Monitor the FDA approval status of Amlexanox to assess potential future royalty income.
- Review the burn rate against the $6.8 million cash balance to validate the runway through December 1997.
- Assess the progress of the two product candidates targeted for human testing in H1 1997.